¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"Hepatitis A Virus Vaccine Inactivated And Hepatitis B Vir..."¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 13
  • ¿µ¹®
    ÇѱÛ
  • Marburg virus infection
    ¸¶¸£ºÎ¸£±× ¹ÙÀÌ·¯½º °¨¿°.
  • Marburg virus infection
    ¸¶¸£ºÎ¸£±× ¹ÙÀÌ·¯ ½º°¨¿°.
  • Mareks disease virus
    ¸¶·ºº´¹ÙÀÌ·¯½º
  • Marhurg virus
    ¸¶¸£Çã±×¹ÙÀÌ·¯½º
  • Murray valley encephalitis virus
    ¸Ó·¹À̰è°î ³ú¿°¹ÙÀÌ·¯½º
  • Murray valley encephalitis virus
    ¸Ó·¹À̰è°î ³ú¿° ¹ÙÀÌ·¯½º
  • Nebraska calf diarrhea virus
    ³×ºê¶ó½ºÄ« ¼Ò ¼³»ç ¹ÙÀÌ·¯½º
  • Omsk hemorrhagic fever virus
    ¿È½ºÅ© ÃâÇ÷¿­¹ÙÀÌ·¯½º
  • Onyong-nyong virus
    ¿À´¨´¨¹ÙÀÌ·¯½º
  • Orf virus
    ¾ç ¾Æ±¸Ã¢¹ÙÀÌ·¯½º
  • Parainfluenza virus
    ÆÄ¶óÀÎÇ÷翣ÀÚ¹ÙÀÌ·¯½º(¼Ó).
  • Powassan virus
    Æ÷¿Í»ê¹ÙÀÌ·¯½º
  • RNA virus
    RNA¹ÙÀÌ·¯½º.
  • RNA virus
    RNA ¹ÙÀÌ·¯½º
  • Rift Valley fever virus
    ¸®ÇÁÆ® °è°î¿­¹ÙÀÌ·¯½º
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 13
  • ¿µ¹®
    ÇѱÛ
  • nose and throat, ear [=ENT]
    À̺ñÀÎÈİú
  • nutritional excess and imbalance
    ¿µ¾ç°ú´Ù(ç½å×ΦÒý) ¹× ºÒ±ÕÇü(ÝÕгû¬)
  • oil and fat
    À¯Áö(êúò·).
  • on (and) off effect
    (ÀÚ±Ø)°³½ÃÁ¾·áÈ¿ °ú(ô±Ø°³½ÃÁ¾¿äÈ¿°ú).
  • on (and) off effect
    (ÀÚ±Ø)°³½ÃÁ¾·áÈ¿°ú(ô§Ð½ËÒã·ðûèçüùÍý).
  • one and one-half syndrome
    1 1/2 ÁõÈıº
  • pairing and subgrouping
    ¦Áö¿ò°ú ¼ÒÁý´ÜÈ­(á³ó¢Ó¥ûù)
  • palm and sole system of identification
    ¼öÀå Á·Àú È®Àιý(â¢íæðëî¼ü¬ìãÛö).
  • palm and sole system of identification
    ¼öÀåÁ·ÀúÈ®Àιý(â¢íæðëî¼ü¬ìãÛö).
  • palpation, percussion and auscultation
    ÃËÁø,ŸÁø,ûÁø(õºòàöèòàôéòà).
  • paraffin and wax
    ÆÄ¶óÇɰú ¿Î½º.
  • pepper-and-salt fundus
    ÈÄÃ߼ұݾÈÀú
  • perfusion and diffusion imaging
    °ü·ù È®»ê ¿µ»ó
  • pericarditis,bread and butter
    »§-¹öÅ͸ð¾ç(¡­Ù¼åÆ)
  • period of mature neural groove and immature somite
    ½Å°æ°í¶û¼º¼÷ ¹× ¸öºÐÀý¹Ì¼º¼÷±â
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 13
OPV Oral Polio-Vaccine; °æ±¸¿ë ¼Ò¾Æ¸¶ºñ ¹é½Å
TOPV Trivalent Oral Polio(myelitis) Vaccine; °æ±¸¿ë ¼Ò¾Æ¸¶ºñ È¥ÇÕ¹é½Å
BCG bacille Calmette-Guerin [vaccine]; ballistocardiography, ballistocardiogram; bicolor guaiac test; br...
DPTPM diphtheria-pertussis-tetanus-poliomyelitis-measles [vaccine]
DTaP diphtheria-tetanus-pertussis [vaccine]
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 13
EPSDT Early and Periodic Screening Diagnosis and Treatment
SUPPORT Study to Understand Prognoses and Preferences for Outcomes and Risks of Treatment
CAR Coxsackie virus and adenovirus receptor
FMDV Foot and Mouth Disease Virus
HSV-2 Herpes Simplex Virus type I and type 2
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 11 ÆäÀÌÁö: 13
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • virus hemagglutination inhibitor
    ¹ÙÀÌ·¯½º ÀûÇ÷±¸ ÀÀÁý¹ÝÀÀ ¾ïÁ¦ ÀÎÀÚ
  • virus herpes simplex
    ¹ÙÀÌ·¯½º¼º ´Ü¼ø Æ÷Áø
  • virus induced tumor
    ¹ÙÀÌ·¯½º À¯¹ß Á¾¾ç
  • virus inhibitory factor
    ¹ÙÀÌ·¯½º ¾ïÁ¦ ÀÎÀÚ
  • virus keratoconjunctivitis
    À¯Ç༺ °¢°á¸·¿°
    µ¿ÀǾî=e
  • virus meningitis
    ¹ÙÀÌ·¯½º¼º ¼ö¸·¿°
  • virus neutralizing antibody
    ¹ÙÀÌ·¯½º ÁßÈ­Á¦
  • virus respiratory infection
    ¹ÙÀÌ·¯½º¼º È£Èí±â °¨¿°Áõ
  • virus transport medium
    ¹ÙÀÌ·¯½º ¿î¼Û ¹èÁö
  • virus-specific surface antigen
    ¹ÙÀÌ·¯½º ƯÀ̼º Ç¥¸é Ç׿ø ¹ÙÀÌ·¯½º
  • wart virus
    »ç¸¶±Í ¹ÙÀÌ·¯½º
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 13
neonatal hepatitis Hepatitis in the neonatal period presumed to be due to a variety of causes, chiefly viral; characterised by direct and indirect bilirubinaemia, hepatocellular degeneration, and appearance of multinucleated giant cells; may be difficult to distinguish from biliary atresia, but is more likely to end with recovery, although cirrhosis may develop.
Synonym: giant cell hepatitis.
(05 Mar 2000)
subacute hepatitis <pathology> This is a form of continuing liver inflammation that results in liver cell death. Causes include viral infection (hepatitis D, hepatitis B, hepatitis C), autoimmune disease, drug ingestion or metabolic causes. Chronic active hepatitis will lead to hepatic failure and death in a small percentage of these patients.
(27 Sep 1997)
non-A, non-B hepatitis Hepatitis caused by two or more infectious agents not detectable by methods that reveal the presence of hepatitis viruses A and B; one cause, now called type C hepatitis has been identified; may follow blood transfusion and is often seen in chronic renal dialysis patients.
Synonym: NANB hepatitis.
(05 Mar 2000)
non-A, non-B, non-C hepatitis Hepatitis caused by viral organisms other than hepatitis viruses A, B or C.
(05 Mar 2000)
suppurative hepatitis Hepatitis with abscess formation; often amoebic in origin.
(05 Mar 2000)
delta hepatitis Acute or chronic hepatitis caused by the hepatitis delta virus, a defective RNA virus requiring HBV for replication. The acute type occurs in two forms: 1) coinfection, the simultaneous occurrence of hepatitis B virus and hepatitis delta virus infections, which usually is self-limiting; 2) superinfection, the appearance of hepatitis delta virus infection in a hepatitis B virus carrier, which often leads to chronic hepatitis The chronic type appears to be more severe than other types of viral hepatitis.
Synonym: delta hepatitis, hepatitis D.
(05 Mar 2000)
drug-induced hepatitis <hepatology, pathology> Inflammation and hepatocellular damage of the liver that is caused by a drug.
Some medications may cause inflammation of the liver as a drug side effect or drug toxicity. Drugs that are known to cause hepatitis include acetaminophen, isoniazid, halothane, methyldopa, erythromycin and oral contraceptives.
(27 Sep 1997)
duck viral hepatitis An acute, highly contagious disease of young ducklings caused by an enterovirus and characterised by lethargy, spasmodic paddling and rapid death.
(05 Mar 2000)
immunization, hepatitis a When immediate protection against hepatitis a (infectious hepatitis) is needed, immunoglobulins are used. Protection is effective only if given within 2 weeks of exposure and lasts but 2-4 months. Immunoglobulins can be used to protect household contacts of someone with acute viral hepatitis and travelers to regions with poor sanitation and high hepatitis a rates, when the traveler has to depart sooner than the vaccines can take effect (about 2 weeks). Travelers can receive the immunoglobulin and vaccine simultaneously and be protected immediately and for longer term. When immediate protection is not needed, hepatitis a vaccines are considered for individuals in high-risk settings, including frequent world travelers, sexually active individuals with multiple partners, homosexual men, individuals using illicit drugs, employees of daycare centres, and certain health care workers, and sewage workers. Two hepatitis a vaccines called havrix and vaqta are commercially available in the u.s. Both are highly effective and provide protection even after only one dose. Two doses are recommended for adults and 3 doses for children (under 18 years of age) to provide prolonged protection.
(12 Dec 1998)
immunization, hepatitis b Hepatits B (hep B) vaccine gives prolonged protection, but 3 shots over a half year are usually required. In the u.s., all infants receive hep b vaccine. Two vaccines (engerix-b, and recombivax-hb) are available in the us. The first dose of hep b vaccine is frequently given while the newborn is in the hospital or at the first doctor visit following birth. The second dose is given about 30 days after the initial dose. A booster dose is performed approximately six months later. Babies born to mothers testing positive for hep b receive, in addition, hbig (hep b immune globulin) for prompt protection. Older children (11-12 years) are advised to receive a hep b booster as are adults in high-risk situations including healthcare workers, dentists, intimate and household contacts of patients with chronic hep b infection, male homosexuals, individuals with multiple sexual partners, dialysis patients, iv drug users, and recipients of repeated transfusions. Health care workers accidentally exposed to materials infected with hep b (such as needle sticks), and individuals with known sexual contact with hep b patients are usually given both hbig and vaccine to provide immediate and long term protection.
(12 Dec 1998)
immunization, infectious hepatitis See Immunization, hepatitis a.
(12 Dec 1998)
immunization, serum hepatitis See Immunization, hepatitis b.
(12 Dec 1998)
infectious canine hepatitis A disease of dogs, caused by canine adenovirus 1, and characterised by fever, depression, loss of appetite, vomiting, bloody diarrhoea, petechial haemorrhages in the gums, pale mucous membranes, and jaundice.
Synonym: hepatitis contagiosa canis, Rubarth's disease.
(05 Mar 2000)
infectious hepatitis <virology> A form of viral hepatitis, known as infectious hepatitis, due to its ability to be spread through personal contact with oral secretions or stool. Virus will be shed in the stools of an infected individual 2-3 weeks prior to the onset of any symptoms. Hepatitis A may also be transmitted sexually. Symptoms are similar to those of influenza, but the skin and eyes may become yellow. Recent travel to a third world country is a risk factor. There is no specific treatment but infected individuals should avoid potentially hepatotoxic substances.
The virus is a small (27nm diameter) single stranded RNA virus with some resemblance to enteroviruses such as polio.
(27 Sep 1997)
infectious hepatitis immunization See Immunization, hepatitis a.
(12 Dec 1998)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 13
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 13
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 13
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 13
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 13
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 13
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 13
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 13
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 13
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 13
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 13
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 13
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 13
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 13
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 13
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 13
ÅëÇÕ°Ë»ö ¿Ï·á